Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$55.45 USD

55.45
10,808,187

+1.13 (2.08%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $55.46 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Nektar's (NKTR) Q2 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Nektar (NKTR) reports dismal second-quarter 2022 results. The company's operating expenses increased due to restructuring expenses of $106.0 million incurred during the quarter.

Mirati (MRTX) Q2 Loss Narrower Than Expected, Sales Beat

by Zacks Equity Research

Mirati Therapeutics' (MRTX) Q2 earnings and sales beat the mark. The company plans to start early-stage clinical studies for a SOS1 inhibitor by year-end.

Is SPDR Portfolio S&P 500 High Dividend ETF (SPYD) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for SPYD

Pfizer (PFE) Q2 Earnings Top, COVID Products Drive Sales

by Zacks Equity Research

Pfizer (PFE) beats estimates for Q2 earnings and sales. It maintains the sales forecast for COVID products, Comirnaty and Paxlovid.

Biotech Stock Roundup: BMY, BIIB's Q2 Earnings, GILD's Updates & More

by Zacks Equity Research

Earnings updates from Bristol Myers (BMY) and Biogen (BIIB) are a few key highlights from the biotech sector during the past week.

Bristol-Myers (BMY) Q2 Earnings, Sales Beat on Eliquis, Opdivo

by Zacks Equity Research

Bristol-Myers (BMY) earnings and sales beat estimates in the second quarter of 2022 on the back of Eliquis and Opdivo and a lesser decline in sales of Revlimid.

TEVA Beats on Q2 Earnings, to Settle Opioid Lawsuit for $4.3B

by Zacks Equity Research

TEVA reports mixed Q2 results. It lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact. The company agrees to settle opioid lawsuits for as much as $4.25 billion.

Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Bristol Myers (BMY) delivered earnings and revenue surprises of 7.82% and 3.72%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Sheraz Mian headshot

Q2 Earnings Season Scorecard and Analyst Reports for Broadcom, Oracle, & Danaher

by Sheraz Mian

Today's Research Daily features a real-time update on the Q2 earnings season and new research reports on Broadcom (AVGO), Oracle (ORCL), and Danaher (DHR).

Drug, Biotech Stocks' Q2 Earnings on Jul 27: BMY, GSK & More

by Zacks Equity Research

Let's look what is in store for the four drug, biotech companies slated to release quarterly results tomorrow- BMY, GSK, ALKS, TEVA

Bristol-Myers (BMY) to Post Q2 Earnings: What is in the Cards?

by Zacks Equity Research

Investors will likely focus on the demand for Eliquis and Opdivo along with incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q2 results. Operating expenses might have jumped.

Sweta Killa headshot

Healthcare ETFs in Focus Ahead of Q2 Earnings

by Sweta Killa

The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio.

Earnings Preview: Bristol Myers Squibb (BMY) Q2 Earnings Expected to Decline

by Zacks Equity Research

Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Bristol Myers Squibb (BMY) closed at $73.14, marking a -0.81% move from the previous day.

Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for RYH

Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Bristol Myers Squibb (BMY) closed at $74.53, marking a -0.64% move from the previous day.

Rhythm Pharmaceuticals, Inc. (RYTM) Surges 42.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

Rhythm Pharmaceuticals, Inc. (RYTM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Exelixis (EXEL) Cabometyx Combo Study Meets Primary Goal

by Zacks Equity Research

Exelixis'(EXEL) late-stage study evaluating the combination of Cabometyx and Opdivo and Yervoy demonstrates significant improvement in progression-free survival at the primary analysis.

Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RYH)?

by Zacks Equity Research

Sector ETF report for RYH

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

by Zacks Equity Research

Sector ETF report for IHE

Biohaven (BHVN) Begins Phase III Study on SMA Candidate

by Zacks Equity Research

Biohaven (BHVN) commenced enrollment in a phase III study to evaluate its muscle-targeted recombinant protein candidate, taldefgrobep alfa, in patients with SMA.

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XPH

Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed at $75.14 in the latest trading session, marking a -1.42% move from the prior day.

Exelixis (EXEL) Collaborates With Ryvu for Cancer Therapies

by Zacks Equity Research

Exelixis (EXEL) teams up with Ryvu Therapeutics to develop novel STING agonist-based targeted cancer therapies.

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

by Zacks Equity Research

Sector ETF report for XPH